Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.

导出 LinkOut

翻译打印收藏纠错

作者： Jeffrey S,Weber ^[1] ; Reinhard,Dummer ; Veerle,de Pril ; Celeste,Lebbé ; F Stephen,Hodi ; MDX010-20 Investigators

作者单位： Donald A. Adam Comprehensive Melanoma Research Center, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA. jeffrey.weber@moffitt.org ^[1]

主题词老年人(Aged);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤药(Antineoplastic Agents);女(雌)性(Female);人类(Humans);免疫系统(Immune System);男(雄)性(Male);黑色素瘤(Melanoma);中年人(Middle Aged);安慰剂(Placebos)

DOI 10.1002/cncr.27969

PMID 23400564

发布时间 2022-04-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览7

Cancer

2013年119卷9期

1675-82页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.

Cancer

相似文献

Cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.

Cancer

相似文献

Cancer

相关期刊

检索历史清除